Landos Biopharma(LABP) - 2023 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Blacksburg, Virginia 24062 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 (State or other jurisdiction of For the quarterly period ended March 31, 2023 incorporation or organization) P.O. Box 11239 OR ☐ TRANSITIO ...